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Abstract
Erythropoietin protects many organs against the tissue injury and
dysfunction caused by ischaemia/reperfusion and excessive inflam-
mation. This editorial comment discusses the effects of erythro-
poietin in preclinical models of septic shock, endotoxemia, hemor-
rhagic shock, spinal cord trauma and zymosan-induced multiple
organ failure.
Erythropoietin (EPO) is a 34 kDa glycoprotein hormone that
controls the proliferation, differentiation, and survival of
erythroid progenitor cells through an antiapoptotic
mechanism. It has become apparent that EPO protects many
organs, including brain, heart, kidney and liver, against the
injury caused by ischaemia/reperfusion, hemorrhagic shock
and systemic inflammation. In this issue of Critical Care, Kao
and colleagues [1] report their findings in an established
murine model of polymicrobial sepsis.
They found that recombinant human EPO (400 IU/kg) exerts
significant beneficial effects when it is given as late as
18 hours after caecal ligation and puncture (CLP). Although
EPO had no effect on the (small) decline in blood pressure,
the decline in platelet and white blood cell counts, or the rise
in lactate, it significantly increased tissue perfusion and
reduced tissue hypoxia. Within 18 hours after CLP there was
a decline in the number of perfused capillary beds (reduced
oxygen delivery); this, in turn, resulted in an impairment in
mitochondrial electron transport and hence respiration
(measured as increase in mitochondrial NADH fluorescence)
in skeletal musle (extensor digitorum longus). Most notably,
EPO rapidly (within 10 min) reversed both of these effects of
CLP, and hence it increased the number of patent capillaries
and increased mitochondrial function. Unfortunately, the
authors did not measure any parameters of organ injury and
dysfunction, and the model of CLP used did not (within
24 hours) result in any deaths. Thus, it remains to be seen
whether the improvement in oxygen delivery or mitochondrial
function afforded by EPO also results in a significant
improvement in outcome.
The study by Kao and coworkers [1] is of particular
importance because EPO protects the brain [2], heart [3],
kidney [4] and liver [5] against the tissue injury and
dysfunction caused by ischaemia/reperfusion (for review
[6,7]). The pathophysiology of the shock associated with
trauma/haemorrhage also comprises elements of ischaemia/
reperfusion injury (because of hypovolaemia and
resuscitation) as well as excessive inflammation. In 2004, we
reported that administration of EPO (300 IU/kg intravenously)
upon resuscitation reduced the renal dysfunction and liver
injury caused by severe haemorrhage and resuscitation in rat
[8]. These beneficial effects of EPO were associated with a
reduction in tissue (renal) apoptosis secondary to prevention
of activation of caspase-3, -8 and -9. Interestingly, EPO also
prevents motor neurone apoptosis and associated
neurological disability in an experimental model of spinal cord
injury [9].
Low doses of EPO (300 IU/kg intravenously) did not affect
the organ injury/dysfunction caused by high doses (6 mg/kg)
of the Toll-like receptor-4 agonist lipopolysaccharide (LPS)
within 6 hours in the rat [8]. However, higher doses of EPO
(4,000 IU/kg given 30 min before LPS) attenuated the renal
dysfunction (decline in glomerular filtration rate), which
occurred at 16 hours after injection of low-dose LPS
(2.5 mg/kg intraperitoneally) in mouse [10]. This beneficial
effect of EPO in murine endotoxaemia was not due to effects
of EPO on either renal blood flow or apoptosis, but it was
associated with prevention by EPO of a fall in renal tissue
superoxide dismutase activity associated with endotoxaemia.
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Thus, Mitra and coworkers [10] concluded that the observed
beneficial effects of EPO in murine endotoxaemia are
secondary to both antioxidant and anti-inflammatory effects of
EPO, which have been reported in other models of disease
[11]. Thus, the beneficial effects of EPO in rodent models of
endotoxaemia may vary with doses of EPO and LPS, as well
as species (rat or mouse) used. Interestingly, higher doses of
EPO reduce both the systemic inflammation and the organ
injury caused by the Toll-like receptor-2 agonist zymosan in
mouse [12]. Specifically, treatment of mice with EPO
(1,000 IU/kg subcutaneously, 1 and 6 hours after zymosan)
attenuated the signs of local (peritoneal exudation) and
systemic (lung inflammation), as well as organ (lung, liver and
pancreas) injury and dysfunction (kidney) caused by zymosan.
Most notably, EPO reduced the high mortality (70%) caused
by zymosan over the observation period of 7 days [12].
The reported beneficial effects of EPO in preclinical models
of shock, trauma and haemorrhage are exciting, but further
studies are warranted to determine the effects of EPO on
outcome (organ injury/dysfunction and survival) in models of
CLP. Interestingly, in 86 patients admitted to a long-term
acute care facility, administration of weekly recombinant
human EPO (n = 42) resulted in a significant reduction in
exposure to allogeneic red blood cell transfusion and higher
haemoglobin levels than placebo (n = 44) during the initial
42 days of EPO therapy [13]. Although not significant, the
mortality rates in patients treated with EPO (12%) were lower
than in the patients treated with placebo (23%).
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